AAMS Internal Medicine & Therapeutics · Vol. 7 · Issue 3 · 2026-03-01
Targeted Therapy for ANCA-Associated Vasculitis: A Phase II Dose-Finding Study
Hägg S, Nishimura R, Khodjayev SH
Karolinska University Hospital, Stockholm, Sweden; Nagoya University Hospital, Nagoya, Japan; Second Tashkent State Medical Institute, Tashkent, Uzbekistan
Abstract
Phase II dose-finding study evaluating a novel complement C5a receptor inhibitor in 320 patients with ANCA-associated vasculitis, assessing remission rates and safety profile.
Keywords: ANCA vasculitis, targeted therapy, complement inhibition, phase II
Full Text